Treatment of advanced malignant melanoma with high-dose melphalan and autologous bone marrow transplantation. 1983

M A Cornbleet, and T J McElwain, and P J Kumar, and J Filshie, and P Selby, and R L Carter, and D W Hedley, and M L Clark, and J L Millar

Twenty-eight patients with advanced life-threatening metastatic malignant melanoma were treated with high dose (140-260 mgm-2) intravenous melphalan and autologous bone marrow. Cyclophosphamide "priming" 300 mgm-2 i.v. was given to 19 patients one week previously and this resulted in clinical but not histological evidence of amelioration of gastrointestinal toxicity. In 11 patients (43%) there was evidence of tumour response to treatment and in 2 patients complete remissions were observed. However in most patients, responses were short-lived and no patient lived longer than 17 months from start of treatment or 24 months from first recorded evidence of distant metastatic disease.

UI MeSH Term Description Entries
D008297 Male Males
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D008558 Melphalan An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen. Medphalan,Merphalan,Phenylalanine Mustard,Sarcolysine,Sarkolysin,4-(Bis(2-chloroethyl)amino)phenylalanine,Alkeran,L-PAM,Mustard, Phenylalanine
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001772 Blood Cell Count The number of LEUKOCYTES and ERYTHROCYTES per unit volume in a sample of venous BLOOD. A complete blood count (CBC) also includes measurement of the HEMOGLOBIN; HEMATOCRIT; and ERYTHROCYTE INDICES. Blood Cell Number,Blood Count, Complete,Blood Cell Counts,Blood Cell Numbers,Blood Counts, Complete,Complete Blood Count,Complete Blood Counts,Count, Blood Cell,Count, Complete Blood,Counts, Blood Cell,Counts, Complete Blood,Number, Blood Cell,Numbers, Blood Cell
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

M A Cornbleet, and T J McElwain, and P J Kumar, and J Filshie, and P Selby, and R L Carter, and D W Hedley, and M L Clark, and J L Millar
January 1986, Cancer chemotherapy and pharmacology,
M A Cornbleet, and T J McElwain, and P J Kumar, and J Filshie, and P Selby, and R L Carter, and D W Hedley, and M L Clark, and J L Millar
July 1989, Bone marrow transplantation,
M A Cornbleet, and T J McElwain, and P J Kumar, and J Filshie, and P Selby, and R L Carter, and D W Hedley, and M L Clark, and J L Millar
May 1985, Cancer treatment reports,
M A Cornbleet, and T J McElwain, and P J Kumar, and J Filshie, and P Selby, and R L Carter, and D W Hedley, and M L Clark, and J L Millar
January 1979, Experimental hematology,
M A Cornbleet, and T J McElwain, and P J Kumar, and J Filshie, and P Selby, and R L Carter, and D W Hedley, and M L Clark, and J L Millar
December 1989, Onkologie,
M A Cornbleet, and T J McElwain, and P J Kumar, and J Filshie, and P Selby, and R L Carter, and D W Hedley, and M L Clark, and J L Millar
December 1982, American journal of clinical oncology,
M A Cornbleet, and T J McElwain, and P J Kumar, and J Filshie, and P Selby, and R L Carter, and D W Hedley, and M L Clark, and J L Millar
May 1986, Blood,
M A Cornbleet, and T J McElwain, and P J Kumar, and J Filshie, and P Selby, and R L Carter, and D W Hedley, and M L Clark, and J L Millar
January 1982, British journal of cancer,
M A Cornbleet, and T J McElwain, and P J Kumar, and J Filshie, and P Selby, and R L Carter, and D W Hedley, and M L Clark, and J L Millar
April 1985, Transplantation proceedings,
M A Cornbleet, and T J McElwain, and P J Kumar, and J Filshie, and P Selby, and R L Carter, and D W Hedley, and M L Clark, and J L Millar
December 1987, British journal of haematology,
Copied contents to your clipboard!